HARTE-HANKS INC (HHS) Stock Fundamental Analysis

NASDAQ:HHS • US4161962026

2.7496 USD
-0.1 (-3.52%)
Last: Feb 27, 2026, 08:08 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

3

Overall HHS gets a fundamental rating of 3 out of 10. We evaluated HHS against 91 industry peers in the Media industry. HHS has only an average score on both its financial health and profitability. HHS has a valuation in line with the averages, but it does not seem to be growing.


Dividend Valuation Growth Profitability Health

4

1. Profitability

1.1 Basic Checks

  • HHS had negative earnings in the past year.
  • HHS had a positive operating cash flow in the past year.
  • The reported net income has been mixed in the past 5 years: HHS reported negative net income in multiple years.
  • The reported operating cash flow has been mixed in the past 5 years: HHS reported negative operating cash flow in multiple years.
HHS Yearly Net Income VS EBIT VS OCF VS FCFHHS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50M -100M

1.2 Ratios

  • The Return On Assets of HHS (-5.87%) is comparable to the rest of the industry.
  • HHS has a Return On Equity (-27.38%) which is comparable to the rest of the industry.
  • Looking at the Return On Invested Capital, with a value of 5.20%, HHS is in the better half of the industry, outperforming 68.13% of the companies in the same industry.
  • The Average Return On Invested Capital over the past 3 years for HHS is above the industry average of 6.97%.
  • The last Return On Invested Capital (5.20%) for HHS is well below the 3 year average (11.42%), which needs to be investigated, but indicates that HHS had better years and this may not be a problem.
Industry RankSector Rank
ROA -5.87%
ROE -27.38%
ROIC 5.2%
ROA(3y)-0.52%
ROA(5y)1.66%
ROE(3y)13.57%
ROE(5y)N/A
ROIC(3y)11.42%
ROIC(5y)N/A
HHS Yearly ROA, ROE, ROICHHS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K -4K

1.3 Margins

  • With a Operating Margin value of 2.35%, HHS perfoms like the industry average, outperforming 50.55% of the companies in the same industry.
  • In the last couple of years the Operating Margin of HHS has declined.
  • HHS has a Gross Margin of 18.47%. This is in the lower half of the industry: HHS underperforms 73.63% of its industry peers.
  • HHS's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 2.35%
PM (TTM) N/A
GM 18.47%
OM growth 3Y-16.84%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.08%
GM growth 5Y15.62%
HHS Yearly Profit, Operating, Gross MarginsHHS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10 -20 -30

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. Health

2.1 Basic Checks

  • HHS has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
  • The number of shares outstanding for HHS has been increased compared to 1 year ago.
  • Compared to 5 years ago, HHS has more shares outstanding
  • The debt/assets ratio for HHS is higher compared to a year ago.
HHS Yearly Shares OutstandingHHS Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M
HHS Yearly Total Debt VS Total AssetsHHS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

  • An Altman-Z score of 14.57 indicates that HHS is not in any danger for bankruptcy at the moment.
  • The Altman-Z score of HHS (14.57) is better than 96.70% of its industry peers.
  • A Debt/Equity ratio of 0.03 indicates that HHS is not too dependend on debt financing.
  • HHS has a Debt to Equity ratio of 0.03. This is amongst the best in the industry. HHS outperforms 81.32% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF N/A
Altman-Z 14.57
ROIC/WACC0.61
WACC8.52%
HHS Yearly LT Debt VS Equity VS FCFHHS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M -40M

2.3 Liquidity

  • HHS has a Current Ratio of 1.48. This is a normal value and indicates that HHS is financially healthy and should not expect problems in meeting its short term obligations.
  • HHS's Current ratio of 1.48 is in line compared to the rest of the industry. HHS outperforms 58.24% of its industry peers.
  • A Quick Ratio of 1.48 indicates that HHS should not have too much problems paying its short term obligations.
  • HHS has a Quick ratio of 1.48. This is in the better half of the industry: HHS outperforms 60.44% of its industry peers.
Industry RankSector Rank
Current Ratio 1.48
Quick Ratio 1.48
HHS Yearly Current Assets VS Current LiabilitesHHS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 82.08% over the past year.
  • HHS shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -11.07%.
  • Measured over the past years, HHS shows a decrease in Revenue. The Revenue has been decreasing by -3.17% on average per year.
EPS 1Y (TTM)82.08%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1641.5%
Revenue 1Y (TTM)-11.07%
Revenue growth 3Y-1.63%
Revenue growth 5Y-3.17%
Sales Q2Q%-17.03%

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y131.2%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year4.05%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
HHS Yearly Revenue VS EstimatesHHS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M 500M
HHS Yearly EPS VS EstimatesHHS Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -5 -10 -15

More info and screens

Find the best growth stocksShow best growing peers

4

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for HHS. In the last year negative earnings were reported.
  • Based on the Price/Forward Earnings ratio of 2.54, the valuation of HHS can be described as very cheap.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of HHS indicates a rather cheap valuation: HHS is cheaper than 95.60% of the companies listed in the same industry.
  • HHS is valuated cheaply when we compare the Price/Forward Earnings ratio to 28.05, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE N/A
Fwd PE 2.54
HHS Price Earnings VS Forward Price EarningsHHS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

  • HHS's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. HHS is cheaper than 97.80% of the companies in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 1.7
HHS Per share dataHHS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15 20

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for HHS!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

HARTE-HANKS INC

NASDAQ:HHS (2/27/2026, 8:08:34 PM)

2.7496

-0.1 (-3.52%)

Chartmill FA Rating
GICS IndustryGroupMedia & Entertainment
GICS IndustryMedia
Earnings (Last)11-10
Earnings (Next)03-12
Inst Owners31.83%
Inst Owner Change-1.99%
Ins Owners38.21%
Ins Owner Change0%
Market Cap20.37M
Revenue(TTM)166.84M
Net Income(TTM)-5.44M
Analysts80
Price TargetN/A
Short Float %0.93%
Short Ratio4.59
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 2.54
P/S 0.12
P/FCF N/A
P/OCF 12.99
P/B 1.02
P/tB 1.06
EV/EBITDA 1.7
EPS(TTM)-0.74
EYN/A
EPS(NY)1.08
Fwd EY39.3%
FCF(TTM)-0.05
FCFYN/A
OCF(TTM)0.21
OCFY7.7%
SpS22.52
BVpS2.68
TBVpS2.59
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -5.87%
ROE -27.38%
ROCE 6.58%
ROIC 5.2%
ROICexc 5.83%
ROICexgc 5.91%
OM 2.35%
PM (TTM) N/A
GM 18.47%
FCFM N/A
ROA(3y)-0.52%
ROA(5y)1.66%
ROE(3y)13.57%
ROE(5y)N/A
ROIC(3y)11.42%
ROIC(5y)N/A
ROICexc(3y)13.82%
ROICexc(5y)N/A
ROICexgc(3y)14.26%
ROICexgc(5y)N/A
ROCE(3y)14.46%
ROCE(5y)N/A
ROICexgc growth 3Y-19.31%
ROICexgc growth 5YN/A
ROICexc growth 3Y-19.72%
ROICexc growth 5YN/A
OM growth 3Y-16.84%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.08%
GM growth 5Y15.62%
F-Score6
Asset Turnover1.8
Health
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF N/A
Debt/EBITDA 0.06
Cap/Depr 42.46%
Cap/Sales 1.18%
Interest Coverage 250
Cash Conversion 18.33%
Profit Quality N/A
Current Ratio 1.48
Quick Ratio 1.48
Altman-Z 14.57
F-Score6
WACC8.52%
ROIC/WACC0.61
Cap/Depr(3y)122.2%
Cap/Depr(5y)111.4%
Cap/Sales(3y)2.1%
Cap/Sales(5y)1.87%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)82.08%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1641.5%
EPS Next Y131.2%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-11.07%
Revenue growth 3Y-1.63%
Revenue growth 5Y-3.17%
Sales Q2Q%-17.03%
Revenue Next Year4.05%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-57.2%
EBIT growth 3Y-18.2%
EBIT growth 5YN/A
EBIT Next Year198.68%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-103.6%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-87.56%
OCF growth 3YN/A
OCF growth 5YN/A

HARTE-HANKS INC / HHS FAQ

What is the ChartMill fundamental rating of HARTE-HANKS INC (HHS) stock?

ChartMill assigns a fundamental rating of 3 / 10 to HHS.


What is the valuation status for HHS stock?

ChartMill assigns a valuation rating of 4 / 10 to HARTE-HANKS INC (HHS). This can be considered as Fairly Valued.


What is the profitability of HHS stock?

HARTE-HANKS INC (HHS) has a profitability rating of 4 / 10.


Can you provide the financial health for HHS stock?

The financial health rating of HARTE-HANKS INC (HHS) is 5 / 10.